Industry
Biotechnology
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
October 02, 2023 | 2:24 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2023 | 12:43 pm
Portfolio Pulse from Benzinga Newsdesk
September 22, 2023 | 8:07 pm
Portfolio Pulse from Benzinga Insights
August 07, 2023 | 4:13 pm
Portfolio Pulse from Benzinga Insights
August 04, 2023 | 2:12 pm
Portfolio Pulse from richadhand@benzinga.com
July 24, 2023 | 12:57 pm
Portfolio Pulse from Benzinga Insights
July 21, 2023 | 5:24 pm
Portfolio Pulse from Happy Mohamed
July 21, 2023 | 2:17 pm
Portfolio Pulse from Benzinga Insights
July 18, 2023 | 5:47 pm
Portfolio Pulse from Benzinga Insights
July 17, 2023 | 4:17 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.